Biomarkers in Heart Disease
American Heart Association Clinical Series

The book covers both the strengths and pitfalls of currently available markers, and provides information on the most promising biomarkers that are likely to impact practice in the next few years. It is divided into four parts, organized around clinical scenarios rather than individual biomarkers.

This book will help the practicing physician decide which biomarkers to measure, when to measure them, how to interpret the results and how to make decisions based on the test result.

1 Protocols for Diagnosing Myocardial Infarction.

2 Troponin and Other Markers of Necrosis for Risk Stratification in Patients with Acute Coronary Syndromes.

3 Challenges Interpreting Cardiac Troponin Values.

4 Natriuretic Peptides and Inflammatory Markers for Risk Stratification in Patients with Ischemic Heart Disease.

5 Novel Markers in Patients with Suspected ACS.

Part II Biomarkers for Evaluation of Patients with Heart Failure.

6 Use of Natriuretic Peptides in the Diagnosis of Heart Failure.

7 Biomarkers for Risk Stratification in Patients with Heart Failure.

8 Natriuretic Peptides for Disease Monitoring in Patients with Chronic Heart Failure.

Part III Biomarkers for Screening in the Ambulatory Populations.

9 CRP.

10 Newer Markers for Population Screening.

Part IV A Look to the Future.

11 Moving Toward Personalized Medicine.

James de Lemos, MD, Associate Professor of Medicine; J. Fred Schoellkopf, Jr. Chair in Cardiology Research, Director, Coronary Care Unit and Cardiology Fellowship Program, UT Southwestern Medical Center, Dallas, TX, USA.